CeaproTSXV: CZO

Ceapro announces 2005 second quarter financial results

· Issued by Ceapro via CNW
EDMONTON, Aug. 15 /CNW/ - Ceapro Inc. (TSX-V: CZO) today released its
second quarter financial results for 2005. Revenues for the second quarter of
2005 are Ceapro's best to date. Sales topped $1 million for the first time,
marking a significant milestone. Net income for the quarter was $101,481 and a
year to date a loss of $55,983.

Second Quarter Highlights

-   Sales revenues climbed 38% to $1.03 million
-   Net income of $101,000 marks a return to profitability in the second
    quarter
-   Working capital improved to a surplus of $101,000
-   Gross margins increased from 50% to 60%, reflecting higher product
    sales and improved plant efficiencies
-   Introduced new powdered extract to the market
-   Delivered four new prototype products to our partners
-   Increased investment in the commercialization of CeaProve(TM)

"As a result of strong sales, we are driving the Company forward and
making significant progress in growing our business," said Dr. Mark Redmond,
Ceapro's President and CEO. "We look forward to delivering rewards to all of
Ceapro's investors and partners"

Outlook

The initiatives undertaken last year have resulted in an increase in
sales, and our second quarter was the highest revenue quarter in Ceapro's
history. We generated net income of $101,000, and there was significant
improvement in our working capital. The expansion of sales to existing
customers, and the introduction of new products to new Customers has boosted
sales of active ingredients.
We have made strides in the development of CeaProve(TM), our diabetes
screening product, identifying new applications in the areas of diabetes
monitoring and drug dosage determination. The signing of new distribution
agreements for veterinary therapeutic products in Asia and Canada, the
development of new veterinary therapeutic products and their addition to the
Japan distribution agreement all pave the way for increased sales later in
2005.
We continue to pursue additional financings to fund ongoing working
capital requirements and to secure the financial resources required to support
the expected increases in the volume of sales of existing products, the
introduction of new products to existing and new markets, and the further
development of new technology. We intend to implement our operating plans in a
measured and responsible manner. We caution that additional investments may be
required to continue to grow the business and product lines and availability
of these additional investments may affect the pace of growth.

About Ceapro Inc.

Ceapro Inc, an innovation-driven biotechnology company, develops and
commercializes organic products for medical, cosmetic, and animal health
industries using proprietary technology and natural, renewable resources.
Based in Edmonton, Alberta, Ceapro is one of Alberta Venture's Fastest Growing
Companies for 2004 and 2005 and is one of Profit Magazine's Next 100
Companies. Ceapro is also the recipient of the ASTech Award for Outstanding
Commercial Achievement for companies with annual sales of less than
$25 million. Ceapro's shares trade on the TSX Venture Exchange under the
symbol CZO. To learn more about Ceapro, log on to our website at
www.ceapro.com. Shares Outstanding: 36,355,950. Recent Close: $0.28.


The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or the accuracy of this news release.

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the     
forward-looking statements contained herein are reasonable, it can give no
assurance that the Company's expectations are correct. All forward-looking
statements are expressly qualified in their entirety by this cautionary
statement.


<<
CEAPRO INC.
Consolidated Balance Sheets

                                                    June 30  December 31
                                                       2005         2004
                                                 (Unaudited)    (Audited)
-------------------------------------------------------------------------
ASSETS
CURRENT ASSETS
  Cash                                          $   110,316  $    96,266
  Accounts receivable                               596,691      375,160
  Inventories                                       270,424      345,424
  Prepaid expenses and deposits                      52,006       66,473
  Deferred charges                                   75,000       50,000
-------------------------------------------------------------------------

                                                  1,104,437      933,323

RESTRICTED CASH FOR THE PURCHASE OF
 PROPERTY AND EQUIPMENT                              14,550       64,430

PROPERTY AND EQUIPMENT (NET OF
 ACCUMULATED AMORTIZATION)                          704,051      720,067
-------------------------------------------------------------------------

                                                $ 1,823,038  $ 1,717,820
-------------------------------------------------------------------------
-------------------------------------------------------------------------
LIABILITIES
CURRENT LIABILITIES
  Accounts payable and accrued liabilities      $   690,382  $   713,201
  Deferred revenue                                        -       80,000
  Callable debt                                     102,530      122,296
  Current portion of long-term debt                  32,073       28,234
  Current portion of convertible debentures               -       17,510
  Current portion of royalties payable              177,958      104,498
-------------------------------------------------------------------------

                                                  1,002,943    1,065,739

Long-Term Debt                                      455,378      471,766

Royalties Payable                                    92,028       66,249
-------------------------------------------------------------------------

                                                  1,550,347    1,603,754
-------------------------------------------------------------------------
SHAREHOLDERS' EQUITY

SHARE CAPITAL                                     2,209,060    1,995,443
CONTRIBUTED SURPLUS                                 121,988      121,997
DEFICIT                                          (2,058,357)  (2,003,374)
-------------------------------------------------------------------------

                                                    272,691      114,066
-------------------------------------------------------------------------

                                                $ 1,823,038  $ 1,717,820
-------------------------------------------------------------------------
-------------------------------------------------------------------------



CEAPRO INC.
Consolidated Statements of Net Income (Loss) and Deficit
Unaudited

                      Six Months Ended June 30    Quarters Ended June 30
                             2005         2004         2005         2004
----------------------------------------------- -------------------------

Revenue
  Sales               $ 1,420,323  $ 1,308,674  $ 1,031,795  $   747,297
  Cost of goods sold      640,152      613,505      415,849      377,278
----------------------------------------------- -------------------------

  Gross margin            780,171      695,169      615,946      370,019
  Royalties, licenses,
   and product
   development fees        80,000      227,500            -      227,500
----------------------------------------------- -------------------------

                          860,171      922,669      615,946      597,519
----------------------------------------------- -------------------------

Expenses
  General and
   administration         522,166      418,638      319,575      222,556
  Royalties               177,122      179,666      125,200      111,795
  Sales and marketing     119,586       60,649       67,910       28,355
  Amortization             78,820       39,729       39,925       20,525
  Interest on long-term
   and callable debt       22,526        4,698       12,941        2,761
  Interest on
   convertible
   debentures and other     2,347        4,061          769        1,965
----------------------------------------------- -------------------------

                          922,567      707,441      566,320      387,957
----------------------------------------------- -------------------------

Income (loss) from
 operations               (62,396)     215,228       49,626      209,562
----------------------------------------------- -------------------------

Other income (expenses)
  Research and product
   development           (227,226)    (111,336)    (183,026)     (77,710)
  Loss on disposal of
   property and
   equipment                    -       (5,171)           -       (5,171)
  Other income
   (expenses)             234,639      (57,379)     234,881     (198,007)
----------------------------------------------- -------------------------

                            7,413     (173,886)      51,855     (280,888)
----------------------------------------------- -------------------------

Income (loss) before
 income taxes             (54,983)      41,342      101,481      (71,326)

Income Taxes
  Current                  76,000       88,825      102,000       16,121
  Reduction as a result
   of applying non-
   capital losses
   carried forward
   against the current
   period's taxable
   income                 (76,000)     (88,825)    (102,000)     (16,121)
----------------------------------------------- -------------------------

NET (LOSS) INCOME FOR
 THE PERIOD               (54,983)      41,342      101,481      (71,326)

Deficit, beginning
 of period             (2,003,374)  (1,605,637)  (2,159,838)  (1,492,969)
----------------------------------------------- -------------------------

Deficit, end of
 period               $(2,058,357) $(1,564,295) $(2,058,357) $(1,564,295)
----------------------------------------------- -------------------------
----------------------------------------------- -------------------------

Net (loss) income
 per share:
  Basic               $    (0.002) $     0.001  $     0.003  $    (0.002)
----------------------------------------------- -------------------------
----------------------------------------------- -------------------------
  Diluted             $    (0.002) $     0.001  $     0.003  $    (0.002)
----------------------------------------------- -------------------------



CEAPRO INC.
Consolidated Statements of Cash Flows
Unaudited

                      Six Months Ended June 30    Quarters Ended June 30
                             2005         2004         2005         2004
----------------------------------------------- -------------------------

Operating Activities
  Net (loss) income
   for the period     $   (54,983)   $ 41,342  $    101,481  $   (71,326)
  Items not affecting
   cash
    Amortization           78,820      39,729        39,925       20,525
    Loss on disposal
     of property and
     equipment                  -       5,171             -        5,171
    Stock based
     compensation           1,798      17,862           572        4,751
----------------------------------------------- -------------------------

                           25,635     104,104       141,978      (40,879)

Changes in Non-Cash
 Working Capital
 Items
  Accounts receivable    (221,531)   (302,293)     (129,078)    (338,864)
  Inventories              75,000     (57,406)       42,728      (68,822)
  Prepaid expenses
   and deposits            14,467     (62,025)        9,338      (14,481)
  Deferred charges        (25,000)          -        50,000       61,982
  Accounts payable and
   accrued liabilities    (22,819)    231,069      (149,170)     358,980
  Deferred revenue        (80,000)          -             -            -
----------------------------------------------- -------------------------

                         (234,248)    (86,551)      (34,204)     (40,084)
----------------------------------------------- -------------------------

Investing Activities
  Purchase of property
   and equipment          (62,804)    (58,122)      (14,483)     (41,395)
  Restricted cash for
   the purchase of
   property and equipment  49,880           -        11,252            -
----------------------------------------------- -------------------------

                          (12,924)    (58,122)       (3,231)     (41,395)
----------------------------------------------- -------------------------

Financing Activities
  Repayment of
   long-term debt         (12,551)    (39,423)       (7,586)     (19,258)
  Repayment of
   callable debt          (19,766)          -        (9,976)           -
  Repayment of
   convertible
   debenture              (20,000)          -       (20,000)           -
  Proceeds from
   issuance of share
   capital                204,800           -             -            -
  Proceeds from
   exercise of stock
   options                  9,500      27,050             -       14,550
  Increase (decrease)
   in royalties
   payable                 99,239      47,588        47,318       41,997
----------------------------------------------- -------------------------

                          261,222      35,215         9,756       37,289
----------------------------------------------- -------------------------

Increase (decrease)
 in cash                   14,050    (109,458)      (27,679)     (44,190)
Cash at beginning
 of period                 96,266     248,443       137,995      183,175
----------------------------------------------- -------------------------

Cash at end of period $   110,316  $  138,985  $    110,316  $   138,985
----------------------------------------------- -------------------------
----------------------------------------------- -------------------------

Supplementary
 information
  Interest paid       $    28,325  $    9,929  $     14,583  $     5,006

>>
%SEDAR: 00010110E

Ceapro on 6ix

Story so far

Earlier from Ceapro

Later from Ceapro

All Ceapro news releases